This week in pharma highlights the hurdles shaping access: stalled UK drug pricing talks, EU approval for Madrigal’s Rezdiffra, and CVS’s coverage denial for Gilead’s HIV PrEP. For commercial and market access teams, these shifts underscore the need to anticipate payer decisions, adapt strategies, and balance innovation with affordability to drive both patient impact and business success.